In This Article:
The CEO of Klaria Pharma Holding AB (publ.) (STO:KLAR) is Scott Boyer. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This process should give us an idea about how appropriately the CEO is paid.
View our latest analysis for Klaria Pharma Holding AB (publ.)
How Does Scott Boyer's Compensation Compare With Similar Sized Companies?
Our data indicates that Klaria Pharma Holding AB (publ.) is worth kr236m, and total annual CEO compensation was reported as kr1.9m for the year to December 2018. Notably, the salary of kr1.8m is the vast majority of the CEO compensation. We examined a group of similar sized companies, with market capitalizations of below kr1.9b. The median CEO total compensation in that group is kr1.1m.
It would therefore appear that Klaria Pharma Holding AB (publ.) pays Scott Boyer more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn't mean the remuneration is too high. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see, below, how CEO compensation at Klaria Pharma Holding AB (publ.) has changed over time.
Is Klaria Pharma Holding AB (publ.) Growing?
Over the last three years Klaria Pharma Holding AB (publ.) has shrunk its earnings per share by an average of 26% per year (measured with a line of best fit). It achieved revenue growth of 65% over the last year.
The reduction in earnings per share, over three years, is arguably concerning. But on the other hand, revenue growth is strong, suggesting a brighter future. It's hard to reach a conclusion about business performance right now. This may be one to watch. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.
Has Klaria Pharma Holding AB (publ.) Been A Good Investment?
Given the total loss of 3.4% over three years, many shareholders in Klaria Pharma Holding AB (publ.) are probably rather dissatisfied, to say the least. So shareholders would probably think the company shouldn't be too generous with CEO compensation.
In Summary...
We compared the total CEO remuneration paid by Klaria Pharma Holding AB (publ.), and compared it to remuneration at a group of similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.